approxim
million
peopl
live
hiv
million
access
antiretrovir
therapi
art
art
success
control
replic
especi
suppress
hiv
load
restor
immun
function
well
improv
longev
qualiti
life
yet
step
taken
develop
drug
base
rapid
emerg
drug
resist
poor
pharmacokinet
drug
hiv
fusion
inhibitor
block
fusion
virus
cell
final
reduc
cellular
damag
becom
research
focu
gener
accept
viral
fusion
model
viral
envelop
surfac
glycoprotein
bind
sequenti
cell
receptor
coreceptor
trigger
conform
chang
core
structur
determin
xray
crystallographi
reveal
stabl
bundl
consist
central
ntermin
heptad
repeat
nhr
coil
coil
ctermin
heptad
repeat
chr
helic
pack
hydrophob
nhr
groov
antiparallel
past
two
decad
discoveri
fusion
inhibitori
peptid
nhr
chr
region
open
avenu
develop
antivir
agent
although
mani
antifus
peptid
report
show
ideal
antivir
activ
short
halflif
unavoid
drug
resist
make
fusion
inhibitor
still
insuffici
structur
modif
exist
drug
becom
import
way
obtain
new
drug
polyethylen
glycol
peg
conjug
commonli
use
method
improv
pharmacokinet
therapeut
peptid
protein
success
appli
design
drug
initi
experi
kda
peg
kda
peg
conjug
nterminu
improv
pharmaceut
profil
studi
studi
success
synthes
two
longact
fusion
inhibitori
peptid
pegyl
confirm
bind
nhr
form
stabl
analyz
inhibitori
activ
envmedi
fusion
viru
infect
test
pharmacolog
kinet
rat
compli
relev
institut
nation
standard
laboratori
anim
use
licens
syxk
anim
care
experiment
studi
review
ethic
commun
institut
microbiolog
chines
academi
scienc
march
tzmbl
cell
line
obtain
nation
institut
health
nih
aid
research
refer
reagent
program
virus
use
infect
assay
isol
replic
european
research
infrastructur
poverti
relat
diseas
project
inform
consent
sign
sampl
collect
studi
review
institut
research
ethic
commun
chines
center
diseas
control
prevent
peptid
synthes
use
solidphas
fmoc
method
beij
scilight
biotechnolog
llc
beij
china
purifi
hplc
puriti
character
spectra
investig
sitespecif
addit
peg
terminu
use
thiolmaleimid
coupl
reaction
follow
establish
glycosyl
strategi
briefli
prepar
use
conjug
deriv
cystein
residu
ntermini
well
peg
deriv
modifi
methoxypegmaleimid
mpegmal
kda
kda
aqueou
solut
disodium
hydrogen
phosphat
mm
ad
dropwis
manner
stir
mixtur
cysteineincorpor
mg
mpegmal
kda
equival
sodium
phosphat
buffer
ml
mm
ph
adjust
ph
mixtur
result
mixtur
stir
min
room
temperatur
directli
purifi
prepar
hplc
afford
mg
mg
white
powder
hplc
analys
perform
agil
system
california
usa
equip
uv
detector
hplc
chromatograph
condit
follow
agil
column
mm
mm
linear
gradient
mlmin
uv
detect
nm
malditof
mass
spectra
record
bruker
biflex
iii
spectromet
bremer
germani
peptid
nm
incub
equal
molar
concentr
c
peptid
min
phosphatebuff
salin
pb
ph
cd
spectroscopi
acquir
jasco
spectropolarimet
model
use
nm
band
width
nm
step
resolut
nm
room
temperatur
content
calcul
cd
signal
divid
mean
residu
ellipt
nm
thermal
denatur
perform
monitor
ellipt
chang
nm
rate
trisglycin
gel
use
npage
peptid
incub
pb
indic
concentr
min
addit
final
concentr
peptid
gradient
concentr
peptid
respect
incub
anoth
min
sampl
mix
trisglycin
nativ
sampl
buffer
volum
ratio
mixtur
load
onto
well
gel
well
gel
electrophoresi
carri
constant
voltag
v
room
temperatur
h
gel
stain
coomassi
blue
visual
imag
system
cytotox
peptid
tzmbl
cell
measur
briefli
serial
dilut
peptid
initi
concentr
ad
overnight
cultur
cell
plate
incub
day
origin
concentr
reagent
dojindo
japan
ad
cell
incub
h
absorb
nm
nm
measur
use
biotek
epoch
elisa
reader
vermont
usa
room
temperatur
cytotox
concentr
calcul
previous
describ
inhibitori
activ
peptid
envmedi
fusion
determin
briefli
cell
seed
cellswel
six
well
plate
overnight
incub
plasmid
plasmid
transfect
cell
invitrogen
lipofectamin
kit
california
usa
accord
instruct
next
day
tzmbl
cell
express
coreceptor
target
cell
seed
dmem
medium
contain
fetal
bovin
serum
fb
well
plate
third
day
peptid
grade
concentr
ad
plate
cell
transfer
plasmid
encod
env
effector
cell
ad
cell
ratio
percent
inhibit
peptid
envmedi
fusion
calcul
use
luciferas
assay
calcul
previous
describ
inhibit
replic
measur
infect
assay
previous
describ
briefli
cultur
supernat
harvest
tissu
cultur
infecti
dose
determin
tzmbl
cell
differ
initi
concentr
set
depend
peptid
peptid
dilut
dmem
medium
dilut
ad
tzmbl
cell
follow
addit
cultur
h
viral
infect
measur
use
luciferas
assay
inhibitori
activ
peptid
calcul
examin
pharmacolog
kinet
vivo
spragu
sd
rat
use
collect
plasma
report
anim
experi
conduct
ethic
guidelin
approv
institut
laboratori
anim
care
use
committe
chines
academi
scienc
briefli
sd
rat
n
male
femal
week
given
singl
subcutan
inject
dosag
physiolog
salin
small
amount
borax
buffer
ph
ad
solubil
agent
blood
sampl
harvest
tail
vein
inject
differ
time
interv
inject
h
blood
sampl
ad
microtub
contain
small
amount
sodium
heparin
aprotinin
plasma
sampl
collect
centrifug
wholeblood
sampl
gmin
min
test
ex
vivo
activ
previous
describ
highest
dilutionfold
plasma
sampl
caus
inhibit
infect
calcul
base
concentr
activ
peptid
plasma
estim
halflif
pharmacokinet
paramet
calcul
use
modfit
softwar
base
previou
work
ctermin
modif
result
decreas
antivir
activ
sitespecif
modif
compil
nterminu
figur
use
develop
strategi
reaction
proceed
mild
condit
ph
room
temperatur
finish
within
short
period
time
min
afford
nearli
quantit
pegyl
product
purifi
semiprepar
hplc
character
malditof
mass
spectrum
figur
high
puriti
product
obtain
white
powder
bioactiv
studi
figur
explor
affin
pegyl
nhr
peptid
contain
full
bind
region
use
model
suitabl
investig
hiv
fusion
inhibitor
cd
spectroscopi
detect
specif
interact
nhr
peptid
well
pegyl
peptid
like
complex
complex
exhibit
high
content
figur
although
melt
temperatur
defin
midpoint
thermal
unfold
transit
complex
slightli
lower
complex
figur
npage
analysi
show
like
pegyl
peptid
could
combin
form
band
higher
posit
band
individu
pegyl
band
dosedepend
relationship
certain
rang
figur
show
band
npage
carri
net
posit
charg
make
peptid
migrat
gel
inhibitori
activ
pegyl
envmedi
fusion
evalu
use
coreceptorexpress
tzmbl
cell
target
cell
envexpress
cell
effector
cell
peptid
could
effect
inhibit
fusion
nm
figur
also
inhibit
replic
laboratoryadapt
strain
nm
figur
cytotox
pegyl
evalu
tzmbl
cell
expect
peptid
exhibit
low
cytotox
tzmbl
cell
valu
greater
report
suggest
hiv
subtyp
might
affect
suscept
certain
antiretrovir
drug
could
influenc
therapeut
outcom
therefor
studi
test
inhibitori
activ
peptid
strain
isol
circul
china
tabl
result
show
pegyl
peptid
lower
isol
circul
china
compar
especi
subtyp
figur
predomin
inject
drug
user
subtyp
b
isol
highest
pegyl
subtyp
lowest
pegyl
studi
figur
howev
sensit
result
subtyp
need
confirm
owe
small
sampl
size
recombin
subtyp
one
main
mechan
lead
genet
divers
complex
genom
studi
analyz
drug
suscept
uniqu
recombin
form
urf
basic
consist
mean
identifi
inhibitori
activ
pegyl
peptid
known
resist
viral
strain
gener
sever
mutant
carri
amino
acid
substitut
either
singli
combin
correspond
infecti
viru
produc
use
infect
assay
result
show
virus
contain
resist
fold
fold
fold
fold
resist
fold
fold
fold
decreas
compar
fold
tabl
protocol
determin
pharmacokinet
pegyl
rat
shown
figur
inhibitori
activ
plasma
rat
treat
reach
highest
peak
level
h
drop
rapidli
decreas
undetect
level
h
post
inject
plasma
halflif
h
plasma
rat
treat
reach
highest
peak
level
h
drop
slowli
decreas
undetect
level
h
post
inject
figur
base
vitro
ex
vivo
activ
pegyl
inhibit
infect
estim
concentr
activ
peptid
plasma
rat
collect
differ
time
figur
calcul
pharmacokinet
paramet
tabl
plasma
h
respect
longer
h
h
result
suggest
peg
modif
result
signific
decreas
rate
renal
filtrat
peptid
prolong
halflif
peptidebas
hiv
fusion
inhibitor
antihiv
drug
play
import
role
prevent
treat
aid
seri
art
includ
nucleosid
revers
transcriptas
inhibitor
nrti
nonnucleosid
revers
transcriptas
inhibitor
nnrti
integras
inhibitor
ii
proteas
inhibitor
pi
fusionentri
inhibitor
ei
pharmacokinet
enhanc
develop
art
success
transform
infect
chronic
manag
diseas
howev
preval
drug
resist
treatment
effect
develop
resist
administ
drug
hiv
fusion
inhibitor
receiv
widespread
attent
act
extracellularli
prior
invas
host
cell
first
approv
hiv
fusion
inhibitor
us
fda
use
treat
hivinfect
patient
fail
respond
current
antiretrovir
drug
clinic
applic
limit
mainli
due
halflif
call
develop
new
hiv
fusion
drug
mani
approach
develop
improv
pharmaceut
profil
fusion
inhibitor
peptid
engin
strategi
incorpor
salt
bridg
chemic
modif
lipid
albumin
glycan
cholesterol
appli
increas
stabil
antivir
activ
peptid
sequenc
reduc
immunogen
proteolysi
pegyl
abl
prolong
halflif
drug
reduc
clearanc
glomerular
filtrat
reticuloendotheli
system
proteolyt
degrad
huet
cheng
appli
peg
improv
pharmacokinet
properti
first
hiv
fusion
inhibitorenfuvirtid
compar
potent
inhibitor
wide
use
design
templat
quinn
design
assess
preclin
toxicolog
perform
first
inhuman
administr
studi
action
mechan
involv
studi
employ
conveni
econom
strategi
improv
pharmacokinet
explor
action
mechan
method
solv
bottleneck
problem
chemic
modif
multipoint
random
modif
result
reduc
product
activ
complex
composit
low
efficaci
sever
reaction
condit
caus
conform
chang
two
conjug
success
synthes
conjug
show
broad
spectrum
activ
low
cytotox
exhibit
potent
antifus
activ
antivir
activ
isol
sensit
differ
drug
might
affect
mutat
site
subtyp
coreceptor
earlier
studi
measur
hiv
mutat
rate
vivo
determin
forward
mutat
rate
mutat
per
target
base
pair
per
replic
cycl
high
mutat
rate
hiv
gener
genet
divers
set
virus
presenc
absenc
drug
affect
sensit
studi
analyz
drug
suscept
clinic
isol
beij
guangxi
sichuan
anhui
pegyl
compar
subtyp
studi
subtyp
sensit
fusion
inhibitor
subtyp
major
epidem
cluster
circul
mainland
china
thu
fusion
inhibitor
may
promis
candid
treat
prevent
infect
report
earli
stage
infect
coreceptor
gradual
convert
final
convert
strain
viru
studi
mainli
strain
strain
strain
detect
effect
coreceptor
util
antivir
activ
fusion
inhibitor
could
analyz
pegyl
hiv
fusion
inhibitor
describ
numer
studi
prior
pct
patent
chose
analyz
larger
molecular
weight
peg
kda
peg
kda
report
posit
chain
length
peg
conjug
affect
membran
fusion
inhibit
proteolyt
degrad
addit
group
ctermin
peptid
fusion
inhibitor
decreas
antivir
potenc
bulki
polym
shell
might
given
rise
transport
limit
viral
target
exert
overal
neg
impact
antivir
potenc
studi
chose
modifi
smaller
nterminu
tri
find
judici
choic
posit
chain
length
conjug
enabl
access
pegyl
slightli
reduc
fusion
inhibitori
efficaci
compar
nonpegyl
peptid
significantli
improv
proteolyt
stabil
circular
dichroism
spectroscopi
result
show
pegyl
fusion
inhibitor
could
bind
correspond
sequenc
form
high
complex
melt
temperatur
composit
respect
might
one
explan
decreas
antivir
activ
pegyl
compar
modif
studi
indic
pegyl
could
significantli
extend
halflif
consist
previou
studi
differ
studi
shown
immun
system
may
produc
specif
peg
antibodi
result
acceler
blood
clearanc
pegyl
therapeut
earli
stage
cooper
institut
microbiolog
chines
academi
scienc
identifi
plasma
halflif
enf
hplc
result
show
halflif
prolong
due
plasma
uv
absorpt
peak
easili
distinguish
plasma
compon
chose
indirect
method
describ
jiang
colleagu
detect
plasma
halflif
pegyl
peptid
studi
detect
dilut
plasma
differ
time
point
inhibit
viral
replic
base
plasma
halflif
pegyl
peptid
sd
rat
calcul
found
plasma
prolong
suggest
pegyl
better
potenti
develop
would
better
choic
fusion
inhibitor
candid
studi
design
synthes
two
peptid
demonstr
exhibit
potent
antiretrovir
activ
clinic
isol
circul
china
also
long
halflif
